CMED CanniMed Therapeutics Inc

CanniMed Therapeutics Inc. Announces Quarterly Results Release Date

SASKATOON, Saskatchewan--(BUSINESS WIRE)--

CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) announces that it plans to release its financial results for the three months ended January 31, 2018 before markets open on Monday, March 19, 2018.

About CanniMed Therapeutics Inc.

CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products.

CanniMed, through its subsidiaries, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical marijuana system for 13 years and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of product diversion or recalls.

For more information, please visit our websites: www.cannimed.ca (patients) and www.cannimedtherapeutics.com (investors).

EN
16/03/2018

Underlying

CMEDCanniMed Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CanniMed Therapeutics Inc

 PRESS RELEASE
Free
CMED CanniMed Therap...

CanniMed Therapeutics Inc. Announces First Quarter Results

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) today released its unaudited financial results of operations for the three months ended January 31, 2018. The information in this news release should be read in conjunction with the Company’s condensed consolidated interim financial statements and notes thereto (unaudited) for the three months ended January 31, 2018 and the Company’s audited consolidated financial statements and notes thereto for the year ended October 31, 20...

March 19, 2018 1 EN
 PRESS RELEASE
Free
CMED CanniMed Therap...

CanniMed Therapeutics Inc. Announces Quarterly Results Release Date

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) announces that it plans to release its financial results for the three months ended January 31, 2018 before markets open on Monday, March 19, 2018. About CanniMed Therapeutics Inc. CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-comp...

March 16, 2018 1 EN
 PRESS RELEASE
Free
CMED CanniMed Therap...

Changes to CanniMed Therapeutics Board Following Share Take-Up by Auro...

EDMONTON, Alberta & SASKATOON, Saskatchewan--(BUSINESS WIRE)-- Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) announced today that following the successful take up and payment of approximately 86.8% of the issued and outstanding of CanniMed Shares, three Aurora Cannabis appointees will join the CanniMed Board of Directors, effective immediately. The CanniMed Board of Directors will now be comprised of: Mr. John Knowles (L...

March 15, 2018 1 EN
 PRESS RELEASE
Free
CMED CanniMed Therap...

Aurora Cannabis Announces Success in Bid for CanniMed Therapeutics Thr...

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) is advised that Aurora Cannabis Inc. (“Aurora”) has been successful in its offer (the “Offer”) for all issued and outstanding common shares of the Company. The information set out in this press release is based on information provided by Aurora. The number of CanniMed common shares (the “CanniMed Shares”) tendered as at the close of business on March 8, 2018 totals 17,847,341, representing approximately 70.66% of the total outstandi...

March 9, 2018 1 EN
 PRESS RELEASE
Free
CMED CanniMed Therap...

Aurora Cannabis Announces Receipt of Final Regulatory Approval for Can...

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) today announced that Aurora Cannabis Inc. (“Aurora”) announced that it has received a No Action Letter from the Competition Bureau (Canada) regarding Aurora’s offer (the "Offer") to purchase all of the issued and outstanding common shares ("CanniMed Shares") of CanniMed that Aurora does not already own. This approval by the Competition Bureau (Canada) represents the final regulatory approval required before Aurora can begin its take-up of Ca...

February 28, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch